우로키나제(Urokinase) 시장 : 유형별, 최종 사용자별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Urokinase Market By Type (Urokinase Powder, Urokinase Solution) , By End User (Hospital, Clinics) : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,091,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,204,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

우로키나아제 시장

우로키나제 시장은 2023년 18억 달러로 평가되었고, 2024-2033년간 연평균 5.7% 성장하여 2033년에는 31억 달러에 달할 것으로 예상됩니다.

우로키나아제는 혈전 용해제이며, 혈전 용해에 필요한 물질이 체내에서 생성되는 것을 돕습니다. 화학적으로, 우로키나아제는 세린 프로테아제이며, 우로키나아제형 플라스미노겐 활성화 인자(uPA)라고도 합니다. 이 화합물은 처음에 인간의 소변에서 분리되었으며 혈액과 일부 조직의 세포 외 기질에 존재합니다. 이 약물은 정맥 주사로 투여되며 의사의 엄격한 통제하에 투여됩니다. 폐색전증, 급성 심근경색, 심부정맥 혈전증 등의 치료에 사용됩니다.

노인 인구의 급격한 증가와 라이프스타일의 급격한 변화로 인한 심혈관 질환의 유병률 증가는 우로키나아제 시장의 주요 촉진요인입니다. 또한, 제형 개선과 약물 전달 시스템의 발전은 효율적인 치료 솔루션으로 우로키나제에 대한 수요를 증가시키고 있습니다. 현재 우로키나아제의 치료 영역이 확대되고 있으며, 원발성 신증후군과 결핵성 흉막염 치료에 우로키나아제가 효과적임이 입증되면서 시장 성장의 견인차 역할을 하고 있습니다. 결핵성 흉막염 치료에서 항결핵 치료와 우로키나아제의 병용 효과는 단독 치료보다 상대적으로 우수합니다. 우로키나아제의 병용은 잔류 흉막 두께를 감소시키고, 총 흉수량을 증가시키고, 폐 기능을 개선하고, 흉수 흡수 시간을 단축시킬 수 있습니다. 원발성 신증후군의 경우, 우로키나아제는 정맥 혈전 색전증을 예방할 수 있으며 경미한 출혈 사건도 동반됩니다.

그러나 출혈성 합병증의 위험은 여전히 크며, 이는 우로키나제 시장의 성장을 억제하고 있습니다. 또한, 최신 항응고제나 조직 플라스미노겐 활성화 인자(tPA)와 같은 대체 요법이 주류로 자리 잡은 것도 시장 개척에 큰 도전이 되고 있습니다. 한편, 제제 개선을 위한 끊임없는 연구개발 노력은 부작용이 적고 환자의 순응도를 높이는 개량형 제제로서 시장 확대의 새로운 기회를 제공합니다. 예를 들어, 프로우로키나제로 알려진 우로키나제의 새로운 전구체가 현재 임상시험 중에 있습니다. 이 비활성 전구체는 활성형 우로키나아제로 전환될 때 피브린 특이적 생리적 특성이 확실히 관여하여 약물의 효능을 향상시키는 것으로 알려져 있습니다.

부문별 리뷰

우로키나제 시장은 유형, 최종 사용자 및 지역으로 분류됩니다. 유형별로 시장은 우로키나제 분말과 우로키나제 용액으로 나뉩니다. 최종 사용자별로 병원 및 클리닉으로 나뉩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

유형별로 보면, 우로키나아제 용액 부문이 2023년 시장을 장악했습니다.

최종 사용자별로는 병원 부문이 2023년 최대 주주로 나타났습니다.

지역별로는 아시아태평양에서 시장이 급성장하고 있습니다.

본 보고서의 커스터마이징 가능성(추가 비용 및 일정이 필요합니다.)

• 규제 가이드라인
• 고객의 관심사에 따른 기업 프로파일 추가
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 프로파일 확대 목록
• 과거 시장 데이터
• 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 구도

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter의 Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 우로키나아제 시장 : 유형별

• 시장 개요
• 우로키나아제 분말
• 우로키나아제 용액

제5장 우로키나아제 시장 : 최종사용자별

• 시장 개요
• 병원
• 클리닉

제6장 우로키나아제 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국 우로키나아제 시장
  • 캐나다 우로키나아제 시장
  • 멕시코 우로키나아제 시장
• 유럽
  • 주요 시장 동향과 기회
  • 독일 우로키나아제 시장
  • 프랑스 우로키나아제 시장
  • 영국 우로키나아제 시장
  • 이탈리아 우로키나아제 시장
  • 스페인 우로키나아제 시장
  • 기타 유럽 우로키나아제 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 일본 우로키나아제 시장
  • 중국 우로키나아제 시장
  • 호주 우로키나아제 시장
  • 인도 우로키나아제 시장
  • 한국 우로키나아제 시장
  • 기타 아시아태평양 우로키나아제 시장
• 라틴아메리카/중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질 우로키나아제 시장
  • 사우디아라비아 우로키나아제 시장
  • 남아프리카공화국 우로키나아제 시장
  • 기타 라틴아메리카/중동 및 아프리카 우로키나아제 시장

제7장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제8장 기업 개요

• NDpharm
• Wanhua Biochem
• Jiangxi Haoran Bio-Pharma
• Jiangsu Aidea Pharmaceutical
• Techpool
• Microbic Biosystems Inc
• Livzon Pharmaceutical Group Inc.
• Cadila Healthcare Limited
• TAJ Pharmaceuticals Limited
• Microbix Biosystems Inc

LSH

영문 목차

영문목차

Urokinase Market

The urokinase market was valued at $1.8 billion in 2023 and is projected to reach $3.1 billion by 2033, growing at a CAGR of 5.7% from 2024 to 2033.

Urokinase is a clot-busting drug which helps the body produce substances necessary to dissolve blood clots. Chemically, urokinase is a serine protease and is also known as urokinase-type plasminogen activator (uPA). The compound was initially isolated from human urine and is present in blood & extracellular matrix of several tissues. The drug is injected intravenously and is strictly administered under medical supervision. The drug is used to treat several conditions such as pulmonary embolism, acute myocardial infarction, and deep vein thrombosis.

Increase in the prevalence of cardiovascular disorders owing to exponentially growing elderly population and significantly changing lifestyle is a major driver of the urokinase market. In addition, improvements in formulation and advancements in drug delivery systems are boosting the demand for urokinase as an efficient treatment solution. Expansion of the treatment horizon of urokinase is currently trending in the market, with the drug proving to be beneficial for the treatment of primary nephrotic syndrome and tuberculous pleurisy. The combined effect of the drug and antituberculous therapy is comparatively better for the treatment of tuberculous pleurisy, than the therapy alone. The integration of urokinase decreases residual pleural thickness, increases total pleural effusion, improves pulmonary function, and reduces pleural effusion absorption time. In primary nephrotic syndrome, urokinase prevents venous thromboembolism, coupled with minor bleeding events.

However, the risk of bleeding complications remains significant in various individuals, thereby restraining the growth of the urokinase market. Moreover, the predominant usage of alternatives, including latest anticoagulant therapies and tissue plasminogen activator (tPA), is presenting significant challenges for the market development. On the contrary, constant R&D efforts toward the refinement of formulations are presenting novel opportunities for market expansion as these improved formulations exhibit less side effects and enhance the patient compliance. For instance, a fresh precursor of urokinase, known as pro-urokinase, is under clinical trials currently. This inactive precursor ensures the involvement of its fibrin-specific physiologic properties during conversion into active urokinase that are known to enhance the efficacy of the drug.

Segment Review

The urokinase market is segmented into type, end user, and region. On the basis of type, the market is bifurcated into urokinase powder and urokinase solution. As per end user, it is divided into hospital and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the urokinase solution segment dominated the market in 2023.

As per end user, the hospital segment was the highest shareholder in 2023.

Region wise, the market is witnessing rapid expansion in Asia-Pacific.

Competition Analysis

The leading players operating in the global urokinase market include NDpharm, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems Inc, Livzon Pharmaceutical Group Inc., Cadila Healthcare Limited, TAJ Pharmaceuticals Limited, and Microbix Biosystems Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

• Urokinase Powder
• Urokinase Solution

By End User

• Hospital
• Clinics

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• NDpharm
• Wanhua Biochem
• Jiangxi Haoran Bio-Pharma
• Jiangsu Aidea Pharmaceutical
• Techpool
• Microbic Biosystems Inc
• Livzon Pharmaceutical Group Inc.
• Cadila Healthcare Limited
• TAJ Pharmaceuticals Limited
• Microbix Biosystems Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: UROKINASE MARKET, BY TYPE

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Type
• 4.2. Urokinase Powder
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Urokinase Solution
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: UROKINASE MARKET, BY END USER

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By End User
• 5.2. Hospital
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Clinics
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: UROKINASE MARKET, BY REGION

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By Region
• 6.2. North America
  • 6.2.1. Key Market Trends and Opportunities
  • 6.2.2. Market Size and Forecast, By Type
  • 6.2.3. Market Size and Forecast, By End User
  • 6.2.4. Market Size and Forecast, By Country
  • 6.2.5. U.S. Urokinase Market
    • 6.2.5.1. Market Size and Forecast, By Type
    • 6.2.5.2. Market Size and Forecast, By End User
  • 6.2.6. Canada Urokinase Market
    • 6.2.6.1. Market Size and Forecast, By Type
    • 6.2.6.2. Market Size and Forecast, By End User
  • 6.2.7. Mexico Urokinase Market
    • 6.2.7.1. Market Size and Forecast, By Type
    • 6.2.7.2. Market Size and Forecast, By End User
• 6.3. Europe
  • 6.3.1. Key Market Trends and Opportunities
  • 6.3.2. Market Size and Forecast, By Type
  • 6.3.3. Market Size and Forecast, By End User
  • 6.3.4. Market Size and Forecast, By Country
  • 6.3.5. Germany Urokinase Market
    • 6.3.5.1. Market Size and Forecast, By Type
    • 6.3.5.2. Market Size and Forecast, By End User
  • 6.3.6. France Urokinase Market
    • 6.3.6.1. Market Size and Forecast, By Type
    • 6.3.6.2. Market Size and Forecast, By End User
  • 6.3.7. UK Urokinase Market
    • 6.3.7.1. Market Size and Forecast, By Type
    • 6.3.7.2. Market Size and Forecast, By End User
  • 6.3.8. Italy Urokinase Market
    • 6.3.8.1. Market Size and Forecast, By Type
    • 6.3.8.2. Market Size and Forecast, By End User
  • 6.3.9. Spain Urokinase Market
    • 6.3.9.1. Market Size and Forecast, By Type
    • 6.3.9.2. Market Size and Forecast, By End User
  • 6.3.10. Rest of Europe Urokinase Market
    • 6.3.10.1. Market Size and Forecast, By Type
    • 6.3.10.2. Market Size and Forecast, By End User
• 6.4. Asia-Pacific
  • 6.4.1. Key Market Trends and Opportunities
  • 6.4.2. Market Size and Forecast, By Type
  • 6.4.3. Market Size and Forecast, By End User
  • 6.4.4. Market Size and Forecast, By Country
  • 6.4.5. Japan Urokinase Market
    • 6.4.5.1. Market Size and Forecast, By Type
    • 6.4.5.2. Market Size and Forecast, By End User
  • 6.4.6. China Urokinase Market
    • 6.4.6.1. Market Size and Forecast, By Type
    • 6.4.6.2. Market Size and Forecast, By End User
  • 6.4.7. Australia Urokinase Market
    • 6.4.7.1. Market Size and Forecast, By Type
    • 6.4.7.2. Market Size and Forecast, By End User
  • 6.4.8. India Urokinase Market
    • 6.4.8.1. Market Size and Forecast, By Type
    • 6.4.8.2. Market Size and Forecast, By End User
  • 6.4.9. South Korea Urokinase Market
    • 6.4.9.1. Market Size and Forecast, By Type
    • 6.4.9.2. Market Size and Forecast, By End User
  • 6.4.10. Rest of Asia-Pacific Urokinase Market
    • 6.4.10.1. Market Size and Forecast, By Type
    • 6.4.10.2. Market Size and Forecast, By End User
• 6.5. LAMEA
  • 6.5.1. Key Market Trends and Opportunities
  • 6.5.2. Market Size and Forecast, By Type
  • 6.5.3. Market Size and Forecast, By End User
  • 6.5.4. Market Size and Forecast, By Country
  • 6.5.5. Brazil Urokinase Market
    • 6.5.5.1. Market Size and Forecast, By Type
    • 6.5.5.2. Market Size and Forecast, By End User
  • 6.5.6. Saudi Arabia Urokinase Market
    • 6.5.6.1. Market Size and Forecast, By Type
    • 6.5.6.2. Market Size and Forecast, By End User
  • 6.5.7. South Africa Urokinase Market
    • 6.5.7.1. Market Size and Forecast, By Type
    • 6.5.7.2. Market Size and Forecast, By End User
  • 6.5.8. Rest of LAMEA Urokinase Market
    • 6.5.8.1. Market Size and Forecast, By Type
    • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

• 7.1. Introduction
• 7.2. Top Winning Strategies
• 7.3. Product Mapping of Top 10 Player
• 7.4. Competitive Dashboard
• 7.5. Competitive Heatmap
• 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

• 8.1. NDpharm
  • 8.1.1. Company Overview
  • 8.1.2. Key Executives
  • 8.1.3. Company Snapshot
  • 8.1.4. Operating Business Segments
  • 8.1.5. Product Portfolio
  • 8.1.6. Business Performance
  • 8.1.7. Key Strategic Moves and Developments
• 8.2. Wanhua Biochem
  • 8.2.1. Company Overview
  • 8.2.2. Key Executives
  • 8.2.3. Company Snapshot
  • 8.2.4. Operating Business Segments
  • 8.2.5. Product Portfolio
  • 8.2.6. Business Performance
  • 8.2.7. Key Strategic Moves and Developments
• 8.3. Jiangxi Haoran Bio-Pharma
  • 8.3.1. Company Overview
  • 8.3.2. Key Executives
  • 8.3.3. Company Snapshot
  • 8.3.4. Operating Business Segments
  • 8.3.5. Product Portfolio
  • 8.3.6. Business Performance
  • 8.3.7. Key Strategic Moves and Developments
• 8.4. Jiangsu Aidea Pharmaceutical
  • 8.4.1. Company Overview
  • 8.4.2. Key Executives
  • 8.4.3. Company Snapshot
  • 8.4.4. Operating Business Segments
  • 8.4.5. Product Portfolio
  • 8.4.6. Business Performance
  • 8.4.7. Key Strategic Moves and Developments
• 8.5. Techpool
  • 8.5.1. Company Overview
  • 8.5.2. Key Executives
  • 8.5.3. Company Snapshot
  • 8.5.4. Operating Business Segments
  • 8.5.5. Product Portfolio
  • 8.5.6. Business Performance
  • 8.5.7. Key Strategic Moves and Developments
• 8.6. Microbic Biosystems Inc
  • 8.6.1. Company Overview
  • 8.6.2. Key Executives
  • 8.6.3. Company Snapshot
  • 8.6.4. Operating Business Segments
  • 8.6.5. Product Portfolio
  • 8.6.6. Business Performance
  • 8.6.7. Key Strategic Moves and Developments
• 8.7. Livzon Pharmaceutical Group Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Key Executives
  • 8.7.3. Company Snapshot
  • 8.7.4. Operating Business Segments
  • 8.7.5. Product Portfolio
  • 8.7.6. Business Performance
  • 8.7.7. Key Strategic Moves and Developments
• 8.8. Cadila Healthcare Limited
  • 8.8.1. Company Overview
  • 8.8.2. Key Executives
  • 8.8.3. Company Snapshot
  • 8.8.4. Operating Business Segments
  • 8.8.5. Product Portfolio
  • 8.8.6. Business Performance
  • 8.8.7. Key Strategic Moves and Developments
• 8.9. TAJ Pharmaceuticals Limited
  • 8.9.1. Company Overview
  • 8.9.2. Key Executives
  • 8.9.3. Company Snapshot
  • 8.9.4. Operating Business Segments
  • 8.9.5. Product Portfolio
  • 8.9.6. Business Performance
  • 8.9.7. Key Strategic Moves and Developments
• 8.10. Microbix Biosystems Inc
  • 8.10.1. Company Overview
  • 8.10.2. Key Executives
  • 8.10.3. Company Snapshot
  • 8.10.4. Operating Business Segments
  • 8.10.5. Product Portfolio
  • 8.10.6. Business Performance
  • 8.10.7. Key Strategic Moves and Developments

관련자료